ELIMINATE trial is evaluating LBP-EC01 for treating urinary tract infections caused by drug-resistant E. coli Funding to support advancement into Part 2 of ELIMINATE trial RESEARCH TRIANGLE PARK,...
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, announced that the ELIMINATE trial has begun enrolling patients and the first patient has been treated. ELIMINATE is a registration-enabling Phase 2/3 clinical trial of lead candidate LBP-EC01, a CRISPR-enhanced bacteriophage (crPhage®) precision medicine, for the treatment of urinary tract infections (UTIs) caused by Escherichia coli (E. coli) bacteria.
Locus Biosciences—a clinical-stage biotech developing a new class of CRISPR-based antibacterial drugs—just closed a $35 million financing round with backing from Johnson & Johnson.
Proceeds will support product development and expansion of in-house cGMP manufacturing capabilities Company anticipates initiating Phase 2 trial of CRISPR-Cas3-enhanced bacteriophage precision...
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial and inflammatory diseases, today announced that the company has entered a credit facility of up to $25 million with Hercules Capital, Inc. (NYSE: HTGC), a specialty financing lender for life science and technology companies. The funds under the facility will be available in tranches upon the achievement of specific clinical and business milestones.
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Locus Biosciences, a clinical-stage biotechnology company, announced today the completion of its Phase 1b clinical trial of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage (crPhage™) precision medicine product targeting Escherichia coli (E. coli) bacteria causing urinary tract infections (UTIs).